Nanobiotix SA
PAR:NANO

Watchlist Manager
Nanobiotix SA Logo
Nanobiotix SA
PAR:NANO
Watchlist
Price: 3.5 EUR -1.63% Market Closed
Market Cap: 165.9m EUR
Have any thoughts about
Nanobiotix SA?
Write Note

Nanobiotix SA
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Nanobiotix SA
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Nanobiotix SA
PAR:NANO
Revenue
€36.2m
CAGR 3-Years
1 063%
CAGR 5-Years
242%
CAGR 10-Years
70%
Valneva SE
PAR:VLA
Revenue
€229.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
G
Genfit SA
PAR:GNFT
Revenue
€84m
CAGR 3-Years
151%
CAGR 5-Years
61%
CAGR 10-Years
29%
Inventiva SA
PAR:IVA
Revenue
€15.6m
CAGR 3-Years
255%
CAGR 5-Years
37%
CAGR 10-Years
N/A
Eurobio Scientific SA
PAR:ALERS
Revenue
€144.2m
CAGR 3-Years
-13%
CAGR 5-Years
21%
CAGR 10-Years
17%
OSE Immunotherapeutics SA
PAR:OSE
Revenue
€83.4m
CAGR 3-Years
83%
CAGR 5-Years
33%
CAGR 10-Years
N/A
No Stocks Found

Nanobiotix SA
Revenue Breakdown

Breakdown by Geography
Nanobiotix SA

Not Available

Breakdown by Segments
Nanobiotix SA

Total Revenue: 30.1m EUR
100%
Other Sales: 5k EUR
0%
Services: 5k EUR
0%

Nanobiotix SA
Glance View

Market Cap
164.9m EUR
Industry
Biotechnology

Nanobiotix SA engages in the development of nanoparticle-based technologies for the treatment of cancer. The company is headquartered in Paris, Ile-De-France and currently employs 100 full-time employees. The company went IPO on 2012-10-29. The firm is engaged in developing nanoparticle technology. The firm designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. The firm develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The firm's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) plays a seminal role in the potential cure and gives the systemic treatment a better chance to increase life expectancy. NanoXray products are developed to selectively increase the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.

NANO Intrinsic Value
5.23 EUR
Undervaluation 33%
Intrinsic Value
Price

See Also

What is Nanobiotix SA's Revenue?
Revenue
36.2m EUR

Based on the financial report for Jun 30, 2024, Nanobiotix SA's Revenue amounts to 36.2m EUR.

What is Nanobiotix SA's Revenue growth rate?
Revenue CAGR 10Y
70%

The average annual Revenue growth rates for Nanobiotix SA have been 1 063% over the past three years , 242% over the past five years , and 70% over the past ten years .

Back to Top